Indian CDMO Sector Growth Trends: Monthly Industry News 2025

April 6, 2026

Introduction

The landscape of the Indian CDMO sector growth trends has witnessed a transformative shift over the past thirty days, signaling a departure from traditional manufacturing toward a high-value innovation model. As global pharmaceutical giants increasingly seek to de-risk their supply chains, India has emerged as a primary beneficiary of the “China Plus One” strategy and the legislative ripples of the U.S. BIOSECURE Act. This month saw major Indian CDMO expansions and acquisitions, driven by private investment and supportive policies, reinforcing India’s growing role in biologics and complex API manufacturing.

Macroeconomic Drivers: Reaching the $30 Billion Milestone

The current fiscal period has highlighted India’s rapid ascent toward becoming a global pharmaceutical powerhouse. India’s pharma exports near $30 billion, fueled by CDMO growth and GCC expansion.

The global CRDMO market is set to reach $303 billion by 2028, with Indian CDMOs gaining share through advanced manufacturing and GCC adoption.

Consolidation and M&A: Building Global Powerhouses

The month of December 2025 has been characterized by significant consolidation, as Indian firms seek the scale required to compete with global titans like Lonza and Thermo Fisher. A landmark development this month is the final regulatory clearance for the merger between Suven Pharmaceuticals and Cohance Lifesciences [3.2].The merger forms a $1 billion CDMO focused on ADCs, oligonucleotides, and complex small molecules.

By uniting Suven’s commercial strength with Cohance’s specialized chemistry, the combined entity targets preferred-partner status with global innovators. Similarly, Senores Pharma announced its intent to acquire 100% of Apnar Pharma for approximately ₹91 crore, effectively absorbing 46 ANDAs and a robust CMO/CDMO pipeline focused on the U.S. market [2]. This scaling trend reflects sponsor demand to consolidate supply chains under one CDMO to enable smoother technology transfer.

The Biologics Revolution: Injectables and ADCs

Indian CDMO growth shows a strong pivot to biologics and sterile injectables, with large molecules nearing 15% CAGR.

Key investments reported this month include:

Sanofi’s Expansion: A massive $437 million outlay in Hyderabad focused on pre-filled syringes and lyophilized oncology products, reflecting deep confidence in local sterile manufacturing expertise [8.2].
Aurigene’s New Facility: The opening of a 70,000-square-foot monoclonal antibody plant in Genome Valley, highlighting the industry’s shift toward mammalian cell culture [8.2].
Enzene Biosciences: A subsidiary of Alkem Laboratories, Enzene won a CPHI Manufacturing Excellence award for its EnzeneX™ platform and is launching its first U.S. continuous manufacturing site in New Jersey.

Geopolitical Tailwinds: The BIOSECURE Act and Supply Chain Reshoring

The U.S. BIOSECURE Act continues to act as a major catalyst for the Indian CDMO sector growth trends. U.S. restrictions on Chinese-linked biotech are boosting RFP demand for Indian CDMOs, with early interest rising despite delayed financial impact.

Piramal Pharma is uniquely positioned with five manufacturing sites across North America and nine in India, allowing them to offer a “hybrid” model that balances cost-efficiency with geographic security [4.1]. Furthermore, Syngene International has observed a 50% rise in enquiries since the Act was first introduced, indicating a long-term rebalancing of the global pharmaceutical supply chain [9.2].

Digital Transformation: AI and Industry 4.0

Innovation in the Indian CDMO sector growth trends is increasingly being defined by bits and bytes as much as by flasks and beakers. This month, several CDMOs have integrated Artificial Intelligence (AI) to optimize process development and reduce time-to-market. For example, Mankind Pharma has leveraged AI for predictive maintenance and adaptive process control across its pilot plants, significantly cutting scrap rates and improving yield [8.2].

Digitalization is also helping Indian firms overcome the “trust gap” in regulatory compliance. By deploying real-time data analytics and automated inspection systems, companies like Aragen Life Sciences are ensuring that every batch meets the stringent standards of the US FDA and EMA. Aragen expects N-1 perfusion and intensified manufacturing to become standard for biologics by 2026.

Environmental, Social, and Governance (ESG) Excellence

Sustainability has moved from a corporate social responsibility checkbox to a core competitive differentiator in the Indian CDMO sector growth trends. This month, Aragen Life Sciences celebrated its EcoVadis Platinum certification, placing it in the top 1% of companies globally for sustainability initiatives [5.1].

Global pharmaceutical partners are increasingly requiring their CDMOs to be carbon-neutral. Sustainability investments and single-use bioreactors are reducing contamination, water use, and energy demand.

Market Challenges and Strategic Outlook

Despite the buoyant growth, the sector is not without its hurdles. This past month, companies have grappled with:

Talent Scarcity: Talent shortages in bioinformatics and cell biology continue to constrain CDMO growth in hubs like Hyderabad and Bengaluru.
API Price Volatility: A downward trend in API prices has impacted the margins of players like Akums Drugs, which reported a dip in net profits despite steady revenue [4.2].
Regulatory Scrutiny: The persistent threat of US FDA warning letters necessitates constant vigilance and investment in quality management systems [8.2].

Nevertheless, the outlook remains overwhelmingly positive. India’s contract manufacturing market is set to double by 2030, driving more complex and innovation-led CDMO output.